Moreover, it was recently shown that sustained DNA methyltransferase 1 inhibition with frequent weekly lower doses of DAC combined with VEN shows an 88% overall response rate in AML, MDS, and CMML, compared to 64% of the cohort treated with standard dosing HMA/VEN [36]. Here, DNMT1 is linked to acute myeloid leukemia.